Guselkumab in moderately to severely active ulcerative colitis: Another interleukin-23p19 subunit inhibitor or more?
The QUASAR clinical development program evaluated the efficacy of guselkumab-an IL-23p19 subunit inhibitor-for the treatment of moderate-to-severe ulcerative colitis.<sup>1</sup> Guselkumab demonstrated rapid control of symptoms, as well as significant rates of objective disease remission. However, real-world evidence will be crucial to confirm these findings in patient subgroups that were not included in the QUASAR program.
Authors
- Ambrogio Orlando (ORCID: https://orcid.org/0000-0002-5298-2638)
- Fabio Salvatore Macaluso (ORCID: https://orcid.org/0000-0001-5128-3846)
Institutions
- Ospedale Vincenzo Cervello (IT)
Publication Details
- Journal
- Med
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.medj.2025.100605
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82